Evidence map›Paper›PMID 39707542›Full record

ArticleJournal of cardiothoracic surgery2024

Long-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT.

Hirokazu Watari, Ryu Kanzaki, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Hideyuki Arita, Koji Konishi, Jiro Okami

Abstract read
In one paragraph

Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hirokazu WatariDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Ryu KanzakiDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan. rkanzaki@tj8.so-net.ne.jp.
Akiisa OmuraDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Sachi KawagishiDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Ryo TanakaDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Tomohiro ManiwaDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Hideyuki AritaDepartment of Neurosurgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Koji KonishiDepartment of Radiation Oncology, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Jiro OkamiDepartment of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment.

methodsWe retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019.

resultsThe median follow-up period was 60 months. The 5-year recurrence-free survival rate and overall survival rates after pulmonary resection were 31.8% and 58.7%, respectively. In the univariate analysis, pathological N0 status was significantly associated with better recurrence-free survival, but not overall survival. The median survival after recurrence was 24 months. Aggressive brain treatment at sites of recurrence and the use of TKIs after recurrence have significantly prolonged prognosis.

conclusionsThe long-term outcomes in patients with synchronous oligometastatic NSCLC with brain metastases who underwent bifocal treatment, including pulmonary resection, were favorable. In particular, bifocal treatment may provide a chance for cure in patients without lymph node involvement.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTreatment OutcomeBifocal treatmentBrain metastasisNSCLCOligometastasesPET/CTTKI

Identifiers

PMID39707542
PMCPMC11662547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.